Bioxytran, Inc. (OTCMKTS:BIXT) Sees Large Drop in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) was the target of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 10,300 shares, a decline of 86.7% from the December 15th total of 77,600 shares. Based on an average trading volume of 153,100 shares, the short-interest ratio is presently 0.1 days.

Bioxytran Trading Down 2.6 %

BIXT traded down $0.00 during midday trading on Wednesday, hitting $0.09. 35,566 shares of the company were exchanged, compared to its average volume of 349,346. The company’s 50 day simple moving average is $0.09 and its 200 day simple moving average is $0.10. The firm has a market capitalization of $8.03 million, a price-to-earnings ratio of -9.25 and a beta of -0.55. Bioxytran has a 1-year low of $0.06 and a 1-year high of $0.15.

Bioxytran Company Profile

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.